APM
Aptorum Group
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 0
Sell signal 1
RSI Overbought
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About APM
Aptorum Group Limited
A clinical stage biopharmaceutical company focused on the field of oncology, autoimmune and infectious diseases
17 Hanover Square, London W1S 1BN, United Kingdom
--
Zhilin Group, formerly known as APTUS Holdings Limited and STRIKER ASIA OPPORTUNITIES FUND CORPORATION, was incorporated as a limited liability company under the laws of the Cayman Islands on September 13, 2010. The Company is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum's product line has also been enriched by: (i) building a drug discovery platform to discover new therapeutic assets through: systematic screening of existing approved drug molecules, And a microbiome-based research platform for the treatment of metabolic diseases; (ii) the joint development of PathsDx Test, a new molecular-based rapid pathogen identification and detection diagnostic technology, with Accelerate Technologies Pte Ltd, the commercialization arm of the Science, Technology and Research Authority of Singapore.
Company Financials
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
